ライフサイエンスコーパス: teriparatide

1 for combination to denosumab vs denosumab to teriparatide).

2 hosphonate therapy may blunt the efficacy of teriparatide.

3 < 0.001) in patients treated with 20 mug/day teriparatide.

4 gains in hip BMD that were not observed with teriparatide.

5 atment attenuates the bone-forming effect of teriparatide.

6 eases of 4.1% with alendronate and 7.1% with teriparatide.

7 eosarcoma has been reported in a woman using teriparatide.

8 e combination group (4.2% [3.0]) than in the teriparatide (0.8% [4.1], p=0.0007) and denosumab (2.1%

9 did total-hip BMD (combination, 4.9% [2.9]; teriparatide, 0.7% [2.7], p<0.0001; denosumab 2.5% [2.6]

10 re randomly assigned to receive 24 months of teriparatide (20 mg daily), denosumab (60 mg every 6 mon

11 l alendronate (70 mg weekly) or subcutaneous teriparatide (20 mug daily).

12 ozumab (210 mg once monthly) or subcutaneous teriparatide (20 mug once daily).

13 tal surgery and received daily injections of teriparatide (20 mug) or placebo, along with oral calciu

14 mbination group (9.1%, [SD 3.9]) than in the teriparatide (6.2% [4.6], p=0.0139) or denosumab (5.5% [

15 Intermittent administration of teriparatide, a drug composed of the first 34 amino acid

16 Teriparatide, a PTH1R agonist that inhibits murine vascu

17 Teriparatide, a recombinant form of parathyroid hormone

18 Favorable outcomes have emerged with teriparatide administration in patients with osteonecros

19 assessed outcomes of periodontal surgery and teriparatide administration in vitamin-D-sufficient and

20 a preplanned extension of the denosumab and teriparatide administration study (DATA), in which 94 po

21 The increase in early precursors after teriparatide administration was associated with robust s

22 randomly assigned to receive, in addition to teriparatide and 1000 IU cholecalciferol, 1800 mg calciu

23 Combined teriparatide and denosumab increased BMD more than eithe

24 The DATA study showed that combined teriparatide and denosumab increased bone mineral densit

25 Effects of teriparatide and denosumab on BMD and fractures are uncl

26 We compared combined teriparatide and denosumab with both agents alone.

27 Discontinuing teriparatide and denosumab, however, results in rapidly

28 Teriparatide, as compared with placebo, was associated w

29 s increased in both groups, as expected with teriparatide, but the increases in the 2 calcium groups

30 assigned in a 1:1:1 ratio to receive 20 mug teriparatide daily, 60 mg denosumab every 6 months, or b

31 se originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and thos

32 % [95% CI 5.3-7.9]) than in the denosumab to teriparatide group (2.8% [1.3-4.2], p=0.0002), but had t

33 p (9.1% [6.1-12.0]) than in the denosumab to teriparatide group (4.9% [2.2-7.5]; p=0.0447 for teripar

34 ctures occurred in 25 (4.0%) patients in the teriparatide group and 38 (6.1%) in the risedronate grou

35 occurred in 28 (5.4%) of 680 patients in the teriparatide group and 64 (12.0%) of 680 patients in the

36 occurred in 30 (4.8%) of 680 patients in the teriparatide group compared with 61 (9.8%) of 680 in the

37 Significantly more patients in the teriparatide group had at least one elevated measure of

38 One participant in the denosumab to teriparatide group had nephrolithiasis, classified as be

39 Compared with the placebo group, the teriparatide group showed increased LS aBMD (6.1% +/- 1.

40 ewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% v

41 t the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2+/-

42 sumab group, and p=0.41 for the denosumab to teriparatide group vs the combination to denosumab group

43 nosumab group; p=0.0099 for the denosumab to teriparatide group vs the combination to denosumab group

44 ents in the romosozumab group and 209 in the teriparatide group were included in the primary efficacy

45 mosozumab group compared with 12 (6%) in the teriparatide group with adverse events leading to invest

46 enosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to bo

47 romosozumab group vs 22 [10%] of 214 in the teriparatide group), hypercalcaemia (two [<1%] vs 22 [10

48 enosumab group, p<0.0001 vs the denosumab to teriparatide group).

49 .0% (10.9-17.2) in 27 women the denosumab to teriparatide group, and 16.0% (14.0-18.0) in 23 women in

50 d by -1.8% (-5.0 to 1.3) in the denosumab to teriparatide group, and increased by 2.8% (1.2-4.4) in t

51 atide to denosumab group vs the denosumab to teriparatide group, p=0.30 for the teriparatide to denos

52 y at the total hip had increased more in the teriparatide group.

53 h 3 of 444 patients (0.7%) in the 20 mug/day teriparatide group.

54 ozumab group and -0.6% (-1.0 to -0.2) in the teriparatide group; difference 3.2% (95% CI 2.7 to 3.8;

55 Although teriparatide has been evaluated for the treatment of ost

56 patients exhibited robust BMD increases with teriparatide; however, there was no observed benefit for

57 nt in opposing the anti-apoptotic effects of teriparatide in these cells, thereby maintaining normal

58 arathyroid hormone (PTH) (1-34) (also called teriparatide) in LDLR -/- mice fed diabetogenic diets fo

59 Teriparatide increases osteoblast numbers by suppressing

60 Thus, teriparatide increases the numbers of early cells of the

61 We show that teriparatide increases the numbers of osteoblast precurs

62 th less severe disease (type I), displayed a teriparatide-induced anabolic response, as well as incre

63 Teriparatide-induced elevation of P1NP levels was less p

64 Teriparatide may offer therapeutic potential for localiz

65 that PTH receptor expression is required for teriparatide-mediated increases in early osteoblast prec

66 randomly assigned to romosozumab (n=218) or teriparatide (n=218).

67 ) patients on romosozumab and in 23 (11%) on teriparatide; none were judged treatment related.

68 5), a sclerostin monoclonal antibody, versus teriparatide on bone mineral density (BMD) in women with

69 ut do not directly demonstrate, a benefit of teriparatide on HRQOL.

70 were randomly assigned to receive 20 mug of teriparatide once daily plus oral weekly placebo or 35 m

71 total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alend

72 vitamin D supplements, and self-administered teriparatide or placebo for 6 wks to correspond with oss

73 observations (eg, oestrogen, calcitonin, and teriparatide) or opportunistic repurposing of existing c

74 0 mug recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind

75 or teriparatide to denosumab vs denosumab to teriparatide, p=0.0336 for combination to denosumab vs d

76 ficant impact on CAL and PPD improvements in teriparatide patients at 1 yr, but infrabony defect reso

77 Continued therapy with teriparatide prevented the appearance of adipocytes.

78 f osteoporosis medications (bisphosphonates, teriparatide, raloxifene, and denosumab) compared with p

79 In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosum

80 ores, and if so, to determine the effects of teriparatide (recombinant human parathyroid hormone 1-34

81 Teriparatide, recombinant human PTH(1-34), is likely to

82 vidence that bisphosphonates, denosumab, and teriparatide reduce fractures compared with placebo, wit

83 Teriparatide reduces the risk of nonvertebral and verteb

84 ncrease, whereas switching from denosumab to teriparatide results in progressive or transient bone lo

85 No direct evidence for teriparatide's actions on early cells of the osteoblast

86 density increased more in patients receiving teriparatide than in those receiving alendronate.

87 is significantly lower in patients receiving teriparatide than in those receiving risedronate.

88 l improvement was greater in patients taking teriparatide than in those taking placebo, with a reduct

89 studies have shown favorable responses with teriparatide (the biologically active fragment of PTH) a

90 bolic responses in excess of those seen with teriparatide, the only currently available anabolic skel

91 en N-telopeptide (NTx) levels increased with teriparatide therapy (135% +/- 14% and 64% +/- 10% chang

92 Vertebral vBMD and strength improved with teriparatide therapy (18% +/- 6% and 15% +/- 3% change,

93 eous defects was significantly greater after teriparatide therapy than after placebo beginning at 6 m

94 Unexpectedly, following withdrawal of teriparatide therapy, bone marrow adipocytes increased d

95 us bone mineral density was unchanged in the teriparatide to denosumab group (0.0% [95% CI -1.3 to 1.

96 p bone mineral density increased more in the teriparatide to denosumab group (6.6% [95% CI 5.3-7.9])

97 k bone mineral density increased more in the teriparatide to denosumab group (8.3% [95% CI 6.1-10.5])

98 n the combination to denosumab group and the teriparatide to denosumab group did not differ significa

99 osumab to teriparatide group, p=0.30 for the teriparatide to denosumab group vs the combination to de

100 ination to denosumab group (p=0.0075 for the teriparatide to denosumab group vs the combination to de

101 or between-group comparisons, p=0.13 for the teriparatide to denosumab group vs the denosumab to teri

102 assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assig

103 18.3% (95% CI 14.9-21.8) in 27 women in the teriparatide to denosumab group, 14.0% (10.9-17.2) in 27

104 umab group (8.6% [7.1-10.0]; p=0.0446 vs the teriparatide to denosumab group, p<0.0001 vs the denosum

105 paratide group (4.9% [2.2-7.5]; p=0.0447 for teriparatide to denosumab vs denosumab to teriparatide,

106 menopausal osteoporotic women switching from teriparatide to denosumab, bone mineral density continue

107 t infrabony defect resolution was greater in teriparatide-treated vitamin-D-sufficient vs. -deficient

108 s who are clinically stable, and considering teriparatide treatment in individuals who experience an

109 Teriparatide treatment significantly reduced the risk of

110 ad scans at baseline and 6 mo after starting teriparatide treatment were used to compare response to

111 were 14.4%-14.8%, and treatment response to teriparatide was 23.2%-23.8%.

112 clinical trial in 211 patients treated with teriparatide who consumed <1000 mg phosphorus/d.

113 double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with

114 We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe os